On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. // The Lancet Gastroenterology & Hepatology. – URL: https://www.sciencedirect.com/science/article/pii/S2468125326002128?dgcid=rss_sd_all
On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial. The Lancet Gastroenterology & Hepatology. https://www.sciencedirect.com/science/article/pii/S2468125326002128?dgcid=rss_sd_all
“On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.” The Lancet Gastroenterology & Hepatology.
@article{article68543,
title = {On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial},
journal = {The Lancet Gastroenterology \& Hepatology},
url = {https://www.sciencedirect.com/science/article/pii/S2468125326002128?dgcid=rss_sd_all}
}